| P2093 | author name string | Lukasz Kedzierski | |
| P2860 | cites work | Resistance to Leishmania major induced by tolerance to a single antigen | Q71595277 |
| | Report of the first cases of cutaneous leishmaniasis in East Timor | Q73803985 |
| | Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis | Q74477253 |
| | Analysis of cytokine production by inflammatory mouse macrophages at the single-cell level: selective impairment of IL-12 induction in Leishmania-infected cells | Q74494567 |
| | Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection | Q74844618 |
| | Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection | Q77489424 |
| | Study of the safety, immunogenicity and efficacy of attenuated and killed Leishmania (Leishmania) major vaccines in a rhesus monkey (Macaca mulatta) model of the human disease | Q78626790 |
| | Vector transmission of leishmania abrogates vaccine-induced protective immunity | Q27316727 |
| | Phagosomes are competent organelles for antigen cross-presentation | Q28591811 |
| | Complexities of assessing the disease burden attributable to leishmaniasis | Q33380173 |
| | Sand fly salivary proteins induce strong cellular immunity in a natural reservoir of visceral leishmaniasis with adverse consequences for Leishmania | Q33450546 |
| | Identification of novel Leishmania donovani antigens that help define correlates of vaccine-mediated protection in visceral leishmaniasis | Q33463435 |
| | Cell biology of Leishmania. | Q33774582 |
| | Cross-protective efficacy of a prophylactic Leishmania donovani DNA vaccine against visceral and cutaneous murine leishmaniasis | Q33796005 |
| | Development of a safe live Leishmania vaccine line by gene replacement. | Q33830649 |
| | The role of nitric oxide in innate immunity. | Q33864359 |
| | Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis | Q34008441 |
| | Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis | Q34033343 |
| | Antigen requirements for efficient priming of CD8+ T cells by Leishmania major-infected dendritic cells | Q34033582 |
| | Effects of environmental change on emerging parasitic diseases | Q34102740 |
| | Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies | Q34147052 |
| | Does the Leishmania major paradigm of pathogenesis and protection hold for New World cutaneous leishmaniases or the visceral disease? | Q34347500 |
| | The immunology of susceptibility and resistance to Leishmania major in mice | Q34988360 |
| | Lipophosphoglycan is a virulence factor distinct from related glycoconjugates in the protozoan parasite Leishmania major. | Q35202576 |
| | Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis | Q35437937 |
| | Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response | Q35448239 |
| | The murine model of infection with Leishmania major and its importance for the deciphering of mechanisms underlying differences in Th cell differentiation in mice from different genetic backgrounds | Q35688077 |
| | Centrin gene disruption impairs stage-specific basal body duplication and cell cycle progression in Leishmania | Q35745876 |
| | Leish-111f, a recombinant polyprotein vaccine that protects against visceral Leishmaniasis by elicitation of CD4+ T cells | Q35947234 |
| | Second-generation vaccines against leishmaniasis | Q36101424 |
| | The impact of vector-mediated neutrophil recruitment on cutaneous leishmaniasis. | Q36201666 |
| | Toward a defined anti-Leishmania vaccine targeting vector antigens: characterization of a protective salivary protein | Q36369425 |
| | The Leishmania infantum acidic ribosomal protein P0 administered as a DNA vaccine confers protective immunity to Leishmania major infection in BALB/c mice | Q36376320 |
| | Low dose Leishmania major promotes a transient T helper cell type 2 response that is down-regulated by interferon gamma-producing CD8+ T cells | Q36399080 |
| | Leishmania/HIV co-infections in the second decade | Q36508348 |
| | Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. | Q36678092 |
| | Expression cloning of a protective Leishmania antigen | Q36701227 |
| | Leishmania vaccines: progress and problems. | Q36726750 |
| | Role of sand fly saliva in human and experimental leishmaniasis: current insights | Q36884480 |
| | CD8 cytotoxic T cells in cutaneous leishmaniasis | Q37016265 |
| | In vivo imaging reveals an essential role for neutrophils in leishmaniasis transmitted by sand flies. | Q37021689 |
| | Persistent parasites and immunologic memory in cutaneous leishmaniasis: implications for vaccine designs and vaccination strategies. | Q37128771 |
| | Leishmania major phosphoglycans influence the host early immune response by modulating dendritic cell functions | Q37274842 |
| | First generation leishmaniasis vaccines: a review of field efficacy trials | Q37308029 |
| | Inoculation of killed Leishmania major into immune mice rapidly disrupts immunity to a secondary challenge via IL-10-mediated process. | Q37310681 |
| | Leishmaniasis: current treatment and prospects for new drugs and vaccines | Q37387410 |
| | The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis | Q38250317 |
| | Dendritic cells, but not macrophages, produce IL-12 immediately following Leishmania donovani infection | Q39029010 |
| | Experimental models for leishmaniasis and for testing anti-leishmanial vaccines. | Q39075233 |
| | Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis | Q39495287 |
| | Effective and long-lasting immunity against the parasite Leishmania major in CD8-deficient mice. | Q39572606 |
| | Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis | Q39835347 |
| | Pathogenicity and protective immunogenicity of cysteine proteinase-deficient mutants of Leishmania mexicana in non-murine models | Q40363487 |
| | Lipophosphoglycan is not required for infection of macrophages or mice by Leishmania mexicana | Q40387461 |
| | Kinetoplastid membrane protein-11 DNA vaccination induces complete protection against both pentavalent antimonial-sensitive and -resistant strains of Leishmania donovani that correlates with inducible nitric oxide synthase activity and IL-4 generati | Q40419800 |
| | The regulation of immunity to Leishmania major | Q40444839 |
| | A leucine-rich repeat motif of Leishmania parasite surface antigen 2 binds to macrophages through the complement receptor 3. | Q40569694 |
| | Loss of the GP46/M-2 surface membrane glycoprotein gene family in the Leishmania braziliensis complex | Q41130044 |
| | Human T cell responses to gp63, a surface antigen of Leishmania | Q41656329 |
| | Leishmania antigens are presented to CD8+ T cells by a transporter associated with antigen processing-independent pathway in vitro and in vivo | Q41944679 |
| | Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection | Q42810799 |
| | SIR2-deficient Leishmania infantum induces a defined IFN-gamma/IL-10 pattern that correlates with protection | Q44039696 |
| | Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (Leish-111f) formulated in MPL adjuvant | Q44126498 |
| | Generation of Leishmania mutants lacking antibiotic resistance genes using a versatile hit-and-run targeting strategy | Q44906625 |
| | Early CD44(hi)CD4+ and CD44(hi)CD8+ T cell numbers and the absence of mannose-rich glycoconjugates determine the protective outcome of anti-leishmanial immunity. | Q45985707 |
| | Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. | Q46480653 |
| | Evaluation of an immunochemotherapeutic protocol constituted of N-methyl meglumine antimoniate (Glucantime) and the recombinant Leish-110f + MPL-SE vaccine to treat canine visceral leishmaniasis | Q46711852 |
| | Cutaneous leishmaniasis in red kangaroos: isolation and characterisation of the causative organisms | Q47692224 |
| | Immune elimination of Leishmania major in mice: implications for immune memory, vaccination, and reactivation disease | Q47896273 |
| | Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response | Q47991640 |
| | Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells | Q50335820 |
| | Intracellular replication-deficient Leishmania donovani induces long lasting protective immunity against visceral leishmaniasis. | Q51778296 |
| | Protective immunogenicity of the paraflagellar rod protein 2 of Leishmania mexicana. | Q51820804 |
| | Decreased IL-10 and IL-13 production and increased CD44hi T cell recruitment contribute to Leishmania major immunity induced by non-persistent parasites. | Q51961303 |
| | Role of CD4+ T cells in pathogenesis associated with Leishmania amazonensis infection. | Q52525664 |
| | Failure of a multi-subunit recombinant leishmanial vaccine (MML) to protect dogs from Leishmania infantum infection and to prevent disease progression in infected animals. | Q52659559 |
| | Autochthonous visceral leishmaniasis: a report of a second case in Thailand. | Q52680257 |
| | Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. | Q53884236 |
| | CD8+ T cells are required for primary immunity in C57BL/6 mice following low-dose, intradermal challenge with Leishmania major. | Q53974457 |
| | A natural model of Leishmania major infection reveals a prolonged "silent" phase of parasite amplification in the skin before the onset of lesion formation and immunity. | Q54045902 |
| | Therapy of murine cutaneous leishmaniasis by DNA vaccination. | Q54050407 |
| | Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. | Q54111717 |
| | A Heterologous Prime‐Boost Vaccination Regimen Using ORFF DNA and Recombinant ORFF Protein Confers Protective Immunity against Experimental Visceral Leishmaniasis | Q56749796 |
| | IL-4 Rapidly Produced by Vβ4 Vα8 CD4+ T Cells Instructs Th2 Development and Susceptibility to Leishmania major in BALB/c Mice | Q56987174 |
| | BCG Expressing LCR1 of Leishmania chagasi Induces Protective Immunity in Susceptible Mice | Q58863008 |
| | Protection Against Cutaneous Leishmaniasis Resulting from Bites of Uninfected Sand Flies | Q60211990 |
| | Immune and clinical parameters associated with Leishmania infantum infection in the golden hamster model | Q66829225 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | vaccine | Q134808 |
| P304 | page(s) | 177-185 | |
| P577 | publication date | 2010-05-01 | |
| P1433 | published in | Journal of Global Infectious Diseases | Q6295262 |
| P1476 | title | Leishmaniasis Vaccine: Where are We Today? | |
| P478 | volume | 2 | |